市场调查报告书
商品编码
1261397
2022-2028 年全球子宫切除术设备市场规模、份额、行业趋势分析报告,按疾病类型、最终用户、手术方法、地区展望和预测Global Hysterectomy Device Market Size, Share & Industry Trends Analysis Report By Disease Type, By End User, By Surgical Approach, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,子宫切除术设备市场规模预计将达到 4.505 亿美元,预测期内復合年增长率为 5.5%。
当女性怀孕时,子宫(也称为子宫)是婴儿生长的地方。 通过部分子宫切除术切除子宫,但保留子宫颈。 子宫颈是子宫的颈部。 然后进行全子宫切除术以去除子宫和子宫颈。 此外,还可以通过阴道切口进行子宫切除术,称为阴道子宫切除术。 他们也可能进□□行机器人手术或腹腔镜手术,即通过腹部的小切口插入细长器械。
其他子宫切除术,例如如果您的子宫很大,如果您想检查其他盆腔器官是否有疾病症状,或者如果您的医生认为患者的最佳选择是建议进行开放式手术。您可能需要进行腹式子宫切除术. 子宫切除术可能是治疗子宫癌和宫颈癌的最佳方法。 其他治疗包括放射疗法和化学疗法,具体取决于癌症的类型和阶段。
COVID-19 影响分析
COVID-19 大流行给世界各地的医疗保健专业人员带来了挑战。 结果,资源从其他医疗保健服务中转移,包括子宫操纵器设备行业,用于护理 COVID-19 患者。 在大流行期间,许多患者在寻求妇科手术治疗方面经历了严重的延误。 许多企业的许多部分都受到了 COVID-19 大流行的影响,包括产品需求、运营、供应链、分销网络和产品研发能力。 因此,预计 COVID-19将对子宫切除术设备市场产生重大的早期影响。
市场增长因素
肥胖增加
5-19岁儿童青少年超重和肥胖患病率显着上升,从1975年的约4%上升到2016年的18%以上。底部。 2016 年有超过 1.24 亿儿童和青少年肥胖,比 1975 年 5-19 岁儿童中不到 1% 的比例有所增加。 此外,女性 (40%) 比男性 (35%) 更容易肥胖,并且女性的健康在几个不同方面受到肥胖的显着影响。 因此,越来越多的女性肥胖症预计会导致子宫肌瘤、子宫癌和慢性盆腔疼痛等问题,从而增加对子宫切除手术的需求并推动子宫切除器械市场的增长。
子宫切除术设备的不断进步
医学进步降低了许多手术的风险,现在被认为是微创手术。 这些进步使子宫切除手术比以往任何时候都更安全,对需要手术的女性来说侵入性更小。 机器人手术技术的进步使得通过隐藏在肚脐后面的一英寸切口进行子宫切除术成为可能。 单点机器人子宫切除术具有微创手术的所有优点,并且在大多数情况下不会留下疤痕。
市场製约因素
有无药物治疗或微创手术
当血液供应被切断时,肌瘤会在数周至数月内死亡并缩小。 这种方法可能适用于不想立即怀孕的女性,因为研究表明,这种手术后流产和其他妊娠问题的风险明显更高。 子宫肌瘤切除术是一种在不切除子宫的情况下切除肌瘤的外科手术,允许未来怀孕。 与任何保留子宫的手术一样,肌瘤有復发的可能。 微创手术、激素疗法和药物的可用性可能会改变患者的偏好并限制子宫切除术设备市场的增长。
按疾病类型划分的前景
根据疾病类型,子宫切除术器械市场分为子宫癌、子宫肌瘤、慢性盆腔痛等。 到 2021 年,慢性盆腔疼痛部分将占子宫切除术设备市场的最高收入份额。 这是因为它会使女性骨盆衰弱、持续和慢性不适。 慢性盆腔不适常伴有肠易激综合征、重度抑郁症和盆腔炎综合征等合併症。 持续性骨盆不适是一种复杂的疾病,有多种潜在原因。
最终用户视角
按最终用户划分,子宫切除术设备市场分为医院、门诊手术中心等。 2021 年,门诊手术中心部分在子宫切除术设备市场中占据了相当大的收入份额。 这种增长归因于几个因素,包括对门诊护理的高需求、微创手术的使用增加以及在门诊手术中心进行的腹腔镜手术的可负担性。 由于微创腹腔镜手术术后并发症的风险较低,预计对移动手术设施的需求将会增加。
手术方法的前景
按手术方法,子宫切除术设备市场分为机器人辅助腹腔镜子宫切除术、腹腔镜子宫切除术、经阴道子宫切除术和腹腔镜子宫切除术。 2021 年,腹部子宫切除术部分在子宫切除术设备市场中的收入份额最高。 这归因于改善生活质量等好处,尤其是当患者患有持续性骨盆不适或大量不规则出血时。 通过 6-8 英寸的腹部切口切除子宫。 切口从肚脐到耻骨或沿着耻骨髮际线的顶部。
区域展望
按地区分析了北美、欧洲、亚太地区和拉美地区的子宫切除术器械市场。 北美地区将在 2021 年以最大的收入份额引领子宫切除术设备市场。 这是由于该地区的几个主要参与者和技术改进。 这些领先企业在收购战略中发挥着不可或缺的作用。 此外,该地区不断上升的子宫癌患病率、强大的消费者基础、消费能力和完善的医疗基础设施预计将推动该地区子宫切除术设备市场的扩张。
The Global Hysterectomy Device Market size is expected to reach $450.5 Million by 2028, rising at a market growth of 5.5% CAGR during the forecast period.
The hysterectomy is the name for the surgical surgery used to remove a woman's uterus. Moreover, this procedure can treat various chronic pain disorders, infections, and some forms of cancer. Depending on the goal of the procedure, a hysterectomy can take various forms. The entire uterus is typically removed in these operations. Hysterectomy can be used to treat uncontrollable vaginal bleeding, persistent pelvic pain, and cancer of the uterus, cervix, or ovaries.
Fibroids, which are benign tumors growing in the uterus, and uterine prolapse, which is when the uterus protrudes from the vagina through the cervix, can also be treated with it joined with adenomyosis, which is a condition in which the lining of the uterus grows into the muscles of the uterus, and pelvic inflammatory disease. A lower belly cut, commonly known as the abdomen, is used during an abdominal hysterectomy to remove the uterus, known as an open procedure.
While a woman is pregnant, the uterus, also known as the womb, is where the baby develops. The uterus is removed with a partial hysterectomy, but the womb's neck remains. The cervix is the womb's neck. Then, the uterus and cervix are removed during a complete hysterectomy. Moreover, a vaginal incision can be used to perform a hysterectomy which is called a vaginal hysterectomy. Alternatively, one might have robotic or laparoscopic surgery, which inserts long, thin equipment through tiny belly incisions.
In place of other hysterectomy procedures, one might require an abdominal hysterectomy if: the uterus is enormous; the doctor wants to examine other pelvic organs for illness symptoms; the doctor suggests an open procedure because it might be the best option for the patient, in their opinion. A hysterectomy may be the best course of treatment for uterine or cervical cancer. Other treatment options may include radiation or chemotherapy, depending on the type of cancer and its stage.
COVID-19 Impact Analysis
The COVID-19 pandemic presented difficulties for healthcare practitioners around the world. As a result, resources were diverted from other healthcare services, including the industry for uterine manipulator devices, to care for COVID-19 patients. Many patients experienced significant delays in receiving gynecologic surgical care during the height of the pandemic. Many parts of numerous businesses, including product demand, operations, supply chains, distribution networks, and the capacity to conduct product research and development, are impacted by the COVID-19 pandemic. As a result, COVID-19 is anticipated to impact the market for hysterectomy device greatly in the initial period.
Market Growth Factors
Rising prevalence of obesity
The prevalence of overweight and obesity among children and adolescents aged 5 to 19 has significantly grown, rising from roughly 4% in 1975 to a little over 18% in 2016. More than 124 million children and teens were obese in 2016, up from less than 1% in 1975 among those aged 5 to 19. Furthermore, women (40%) are more likely to be obese than men (35%), and women's health is majorly impacted by obesity in several distinct ways. Hence, the increasing obesity in women is expected to cause issues like fibroids, uterine cancer, or chronic pelvic pain that will increase the requirement for hysterectomies and boost the hysterectomy device market growth.
The constant advancement of devices used in hysterectomy
Medical advancements have reduced the hazards of many surgeries to the point where they are now regarded as minimally invasive procedures. These developments have made hysterectomy surgery safer and less intrusive than ever for women who require this surgical removal of the uterus. A one-inch incision concealed in the belly button can now be used to perform hysterectomies due to the recent advancements in robotic surgery technology. The single-site robotic hysterectomy offers all the advantages of minimally invasive surgery and, in most cases, results in absolutely no scarring.
Market Restraining Factors
Presence of medications and minimally invasive surgeries
The fibroids die and diminish within a few weeks to months once the blood supply is severed. This method might be better suitable for women who don't want to become pregnant shortly because studies have revealed a considerable risk of miscarriage and other pregnancy issues after this operation. Myomectomy, which allows for future pregnancies, is the surgical removal of the fibroids without removing the uterus. There is a chance of fibroid recurrence, like every other uterus-sparing operation. The availability of minimally invasive procedures, hormone therapies, and medicines might shift patients' preference toward them and restrict the hysterectomy device market growth.
Disease Type Outlook
Based on disease type, the hysterectomy device market is segmented into uterine cancer, fibroids, chronic pelvic pain and others. The chronic pelvic pain segment held the highest revenue share in the hysterectomy device market in 2021. This is because it is a debilitating, persistent, chronic discomfort in a women's pelvis. Chronic pelvic discomfort is frequently accompanied by comorbidities such as irritable bowel syndrome, major depressive illness, or pelvic inflammatory syndrome. Persistent pelvic discomfort is a complicated illness with several potential causes.
End User Outlook
On the basis of end user, the hysterectomy device market is divided into hospitals, ambulatory surgical centers and others. The ambulatory surgical centers segment procured a substantial revenue share in the hysterectomy device market in 2021. The growth is attributed to several factors, including a high desire for outpatient treatments, an increase in the use of minimally invasive procedures, and the affordability of laparoscopic procedures performed in ambulatory surgery centers. The demand for mobile surgery facilities is anticipated to rise due to the lower risk of postoperative complications in minimally invasive laparoscopic surgery.
Surgical Approach Outlook
By surgical approach, the hysterectomy device market is classified into robotic assisted laparoscopic hysterectomy, abdominal hysterectomy, vaginal hysterectomy and laparoscopic hysterectomy. The abdominal hysterectomy segment registered the highest revenue share in the hysterectomy device market in 2021. This is owing to the benefits like improving the quality of life, particularly if the patient suffers from persistent pelvic discomfort or heavy, irregular bleeding. Through a six- to eight-inch abdominal incision, the uterus is removed. The incision is either done from the navel to the pubic bone or along the top of the pubic hairline.
Regional Outlook
Region-wise, the hysterectomy device market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region led the hysterectomy device market by generating the maximum revenue share in 2021. This is due to several significant players and technical improvements in the region. These leading players play an essential role in acquisition strategies. Furthermore, the region's rising uterine cancer prevalence, strong consumer base, spending power, and established healthcare infrastructure are anticipated to fuel the hysterectomy device market expansion in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic PLC, B. Braun Melsungen AG, ConMed Corporation, Johnson & Johnson, Richard Wolf GmbH, Karl Storz SE & Co. KG, The Cooper Companies, Inc., Laborie Medical Technologies (Patricia Industries) (Investor AB), Fortimedix Surgical B.V., and Conkin Surgical Instruments Ltd.
Strategies deployed in Hysterectomy Devices Market
Feb-2023: Laborie announced the acquisition of Novonate and its LifeBubble technology, a device used to raise the foetal head, making birth easier and less traumatic for the mother and baby. Together, the companies are focused on advancing the standard of care for neonates in intensive care.
Nov-2022: Medtronic Private Limited, a division of Medtronic PLC announced the launch of the TruClear system, a mechanical hysteroscopic tissue removal for efficient and safe treatment of intra-uterine anomalies (IUA). Unlike other intrauterine abnormality therapy methods, the TruClear device eliminates intrauterine tissue manually instead of employing a high-frequency electric current. The device is intended to facilitate the treatment of intrauterine illnesses in a less invasive and efficient manner, giving patients the choice to maintain the organ and swiftly return to their regular lives.
Sep-2022: Medtronic together with CARE Hospitals Group, introduced the first gynecology (hysterectomy) procedure in the Asia Pacific leveraging the Hugo robotic-assisted surgery (RAS) system. To provide high-quality patient care at reasonable prices, investments in technology-enabled healthcare solutions are essential. High-quality equipment, like a robotic system, aids in accuracy improvement, shortens hospital stays, and speeds up patient recuperation.
Feb-2022: CooperCompanies signed an agreement to acquire Cook Medical's Reproductive Health Business, a company engaged in manufacturing minimally invasive medical devices for obstetrics, fertility, and gynecology markets. The acquisition added delivery devices to the former company's ObGyn portfolio and would expand its international fertility footprint.
Feb-2022: Laborie acquired Clinical Innovations for continuing to support moms, babies, and medical professionals all over the world by investing in and expanding Clinical Innovations' distinctive product line and specialist channels. The company's ability to serve the specific customer call point of obstetricians, gynecologists, neonatologists, and NICU and L&D nurses will be enhanced by Clinical Innovations' already strong and trusted relationships with physicians and nurses.
Dec-2021: CooperCompanies acquired Generate Life Sciences, a provider of donor sperm and egg for fertility cryopreservation service, fertility treatments, and newborn stem cell storage. With this acquisition, the company would be able to offer fertility clinics and OB/GYNs an even stronger service.
May-2021: CooperSurgical took over obp Medical Corporation, a company that focuses on developing and marketing diversified products comprising single-use vaginal speculums with combined LED illumination. The acquisition complemented CooperSurgical's portfolio of OB/GYN medical devices.
Mar-2021: CooperSurgical completed the acquisition of Safe Obstetric Systems, a company engaged in manufacturing medical devices, Fetal Pillow, an FDA-approved product used to raise the foetal head, making the birth easier and less traumatic for the mother and baby, after a fully dilated caesarean section. The acquisition is a perfect fit for CooperSurgical's mission of women's healthcare advancement.
Market Segments covered in the Report:
By Disease Type
By End User
By Surgical Approach
By Geography
Companies Profiled
Unique Offerings from KBV Research